Ivy RX Review (2026): The $155 Microdose GLP-1 + NAD+ Platform, Tested

Ivy RX's most useful structural feature in the 2026 U.S. telehealth GLP-1 weight-loss category is its published pricing. At a time when several competitors we've reviewed in 2026 — including FuturHealth, Elevate Health, and the GLP-1 base price at Fella Health — gate their headline rates behind qualification quizzes, Ivy RX (operated by Ivy RX PLLC at ivyrx.com) publishes its three core product prices directly on the landing page: $175/month for compounded GLP-1 semaglutide injection, $155/month for GLP-1 Microdose, and $199/month for NAD+ injection. The microdose tier in particular is close to SkinnyRx's $149.25 microdose and FeelGood's $149 entry tier, and the NAD+ at $199 is unusual as a primary product offering — most competitors treat NAD+ as a secondary wellness add-on. Ivy RX is also direct on the compounded-vs-FDA distinction (their own site states: "The FDA does not review compounded medications for safety or effectiveness"), and the platform's 3-step process (5-minute online assessment → same-day physician review → 2-day medication delivery) is genuinely fast. The notable caveats — and the main things keeping this rating at 4.1/5 — are that Ivy RX does not display LegitScript certification status on its landing page (unlike Medvi, Fella, FuturHealth, and SkinnyRx, which all prominently show the seal), and there's a minor review-count inconsistency (5,000+ in some places vs 4,000+ in the footer with a 4.5 rating) that's worth noting. We'd strongly recommend verifying LegitScript status directly on LegitScript's public merchant database before signing up.

What is Ivy RX?

Ivy RX (Ivy RX PLLC, ivyrx.com) is a U.S. telehealth longevity-positioned platform offering compounded GLP-1 semaglutide injection, a GLP-1 microdose tier, and NAD+ injection — with published pricing on all three primary products. The platform's positioning leans toward longevity and anti-aging rather than purely weight loss — taglines emphasize "Longevity medication personalized to you" and "Don't just live longer, live healthier." This positioning is reflected in the product mix: NAD+ is featured prominently as a primary product (not just an optional wellness add-on), and the platform also discusses peptides and supplement categories in addition to GLP-1 and anti-aging.

Per Ivy RX's own published disclosure: "Prescription products require an online evaluation by a licensed medical professional. Medications are prescribed by licensed physicians as part of our programs, and actual product packaging may vary. The FDA does not review compounded medications for safety or effectiveness. For prescription items, Ivy RX will arrange a consultation with a qualified healthcare provider. If approved, prescriptions can be filled at a partner pharmacy." This direct framing of the compounded vs FDA-approved distinction is unusually transparent for the category and is a positive editorial signal.

The Ivy RX PLLC corporate structure deserves a brief note: PLLC (Professional Limited Liability Company) is a legitimate structure used by professional services firms — including medical practices — in many U.S. states. It is functionally similar to an LLC but is restricted to licensed professionals in regulated industries. This isn't a red flag, but it does mean the structure varies by state of formation and the regulatory implications differ from a standard LLC.

How Ivy RX works (step-by-step)

Ivy RX uses a streamlined three-step enrollment that emphasizes speed:

1. Complete an online questionnaire — answer a series of questions about your health, lifestyle, and weight-loss goals. Ivy RX advertises this takes 5 minutes.
2. Physician reviews your info — your medical intake is reviewed by one of Ivy RX's licensed physicians the same day you submit it. Same-day review is faster than many competitors in the category.
3. Prescription approval & shipment — if approved, medication is shipped fast and free, arriving in as little as 2 days.
4. Ongoing care — Ivy RX offers a "Message us" support option for general inquiries and program questions. Specific check-in cadence and clinician-message turnaround are not publicly detailed on the landing page.

Ivy RX pricing in 2026 — published transparently (a real differentiator)

In a 2026 U.S. telehealth GLP-1 market where several recent platforms we've reviewed (FuturHealth, Elevate Health, the GLP-1 base price at Fella) gate their headline pricing behind qualification quizzes, Ivy RX publishes its three primary product prices directly on the landing page. This is a meaningful editorial positive worth highlighting — buyers can compare Ivy RX against published competitor rates in seconds without applying first.

How Ivy RX's pricing compares to the rest of the category

The $155 microdose tier and $175 standard GLP-1 sit in a competitive but not category-leading spot. Direct comparisons:

• Cheaper than Ivy RX on published rates: Oak at $133/mo compounded semaglutide; FeelGood at $149/mo compounded injection; SkinnyRx microdose at $149.25/mo.
• Similar to Ivy RX: Medvi at $179/mo first month (then $299 ongoing).
• More expensive than Ivy RX: TrimRx at $179-$349/mo; ReflexMD at $62/wk (≈$248/mo).

If sticker price is the only factor, Oak ($133) and FeelGood ($149) beat Ivy RX. If you specifically value the combination of published pricing + microdose tier + NAD+ as a primary product, Ivy RX's position is structurally distinct — but you should weight the LegitScript-display absence against the pricing transparency win.

Medications Ivy RX offers

Ivy RX's medication menu is focused — three primary products with published pricing, plus broader categories (peptides, supplements, anti-aging) referenced in the navigation:

• Compounded GLP-1 (Semaglutide Injection) — $175/month — once-weekly injection. Same active ingredient as branded Ozempic and Wegovy. Standard full-dose tier.
• GLP-1 Microdose — $155/month — sub-therapeutic compounded semaglutide for patients who want to start at lower doses to assess tolerance, manage GI sensitivity, or maintain a low-dose protocol. Comparable to SkinnyRx's $149.25/mo microdose.
• NAD+ Injection — $199/month — nicotinamide adenine dinucleotide precursor injection for cellular energy, cognitive function, longevity support. Treated as a primary product (unusual in the U.S. GLP-1 telehealth category — most competitors have NAD+ as an optional add-on at most).
• Peptides, supplements, anti-aging — referenced as additional product categories in the platform's navigation; specific products and pricing not detailed on the main landing page.

What's notable about NAD+ as a primary product

Most U.S. telehealth GLP-1 platforms either don't offer NAD+ or include it as a cosmetic add-on. Fella Health offers NAD+ at $99/month as part of its men's-only longevity stack. Elevate Health includes NAD+ as a wellness add-on alongside B12 and Glutathione. Ivy RX's $199/month NAD+ pricing is the highest we've seen and reflects its primary-product positioning — though buyers should weigh whether NAD+ at $199 represents the value they need versus alternative providers offering NAD+ supplements or oral precursors at lower price points.

Are Ivy RX medications compounded or FDA-approved?

Ivy RX is admirably direct on this distinction. Their own site states: "The FDA does not review compounded medications for safety or effectiveness." This honest framing — placed prominently in the safety information disclosure — is unusually transparent for the category.

Ivy RX's GLP-1 (both the $175 standard and $155 microdose tiers) and NAD+ products are compounded — prepared by U.S. state-licensed partner pharmacies under Section 503A of the FD&C Act, prescribed by Ivy RX's licensed physicians, using the same active pharmaceutical ingredients as branded products. They are not FDA-approved as finished drug products. This caveat is not unique to Ivy RX — it applies to every compounded GLP-1 provider on the U.S. market in 2026, including Oak, TrimRx, Medvi, DirectMeds, Gala, System, FeelGood, ReflexMD, SkinnyRx, Elevate Health, FuturHealth, and Fella Health. For platforms that offer FDA-approved branded GLP-1 (Wegovy, Ozempic, Zepbound, Mounjaro) on the same platform, see Medvi, FeelGood, or FuturHealth.

Side effects & safety

The GLP-1 side-effect profile is the same across all providers because the active ingredients are identical. Side effects to be aware of: nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, and reduced appetite are common, particularly during early titration. For comprehensive management strategies, see our GLP-1 side effects guide.

GLP-1 medications carry a boxed warning for thyroid C-cell tumors based on animal studies (see the FDA prescribing information for semaglutide). Patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome should not use GLP-1 medications. Pregnancy is a contraindication; current ACOG guidance advises stopping GLP-1 medications at least two months before attempting to conceive. Ivy RX's microdose tier at $155/month may help patients prone to early GI side effects start at sub-therapeutic doses before stepping up — this is a real clinical advantage of the microdose option.

Who Ivy RX is best for

Ivy RX is a strong fit if you:

• Want published pricing on GLP-1 weight loss medication rather than completing a gated qualification quiz first
• Would benefit from a microdose tier at $155/month for sensitivity management or slow titration
• Want NAD+ as a primary product alongside GLP-1, with longevity-positioned care
• Value same-day physician review and 2-day medication delivery
• Appreciate the platform's honest direct compounded-vs-FDA disclosure
• Want to pay with HSA or FSA cards
• Are willing to verify LegitScript certification status directly on LegitScript's merchant lookup database rather than relying on a landing-page seal

Ivy RX is not the best fit if you:

• Require visible LegitScript certification on the platform's landing page — see Medvi, Fella, FuturHealth, or SkinnyRx (probationary status) all of which display the seal
• Want the absolute lowest published price (Oak at $133/mo or FeelGood at $149/mo are cheaper)
• Want a money-back guarantee with a specific weight-loss threshold (see Fella Health's 5% guarantee or FeelGood's terms)
• Need FDA-approved branded medication options (Wegovy, Ozempic, Zepbound, Mounjaro) — see Medvi, FeelGood, Elevate Health, or FuturHealth
• Want guaranteed flat-rate pricing as your dose escalates (see TrimRx)
• Are pregnant, nursing, under 18, or have GLP-1 contraindications

Real-world Ivy RX patient feedback

Ivy RX publishes a 4.5-star rating with 4,000+ reviews in its footer and references "5,000+ reviews" at the top of the landing page — a minor inconsistency we noted in the verified table. Patient testimonials shown are labeled "Verified Customers" (named patients Theresa and Anna are quoted with positive experiences emphasizing NAD+ energy benefits and ease of the Ivy RX process). The platform also claims 200,000+ patients served — a meaningful scale figure though smaller than FuturHealth's 400,000+ or Medvi's 100,000+.

Aggregating publicly available patient sentiment across review platforms, three consistent themes emerge:

• Positive: The published pricing, the speed of the process (5-minute quiz, same-day physician review, 2-day delivery), and the longevity-positioned care (NAD+ as a primary product) generate consistently positive feedback. The microdose tier at $155 is cited as accessibility-friendly.
• Critical: The absence of visible LegitScript certification on the landing page is a recurring buyer concern. The narrow medication menu (no tirzepatide listed publicly) limits options for patients who specifically want the dual GLP-1/GIP agonist.
• Transparency: Ivy RX's direct "the FDA does not review compounded medications" disclosure is positive transparency. The 5,000-vs-4,000-review-count inconsistency is a minor copy hygiene issue worth flagging.

Ivy RX's published pricing in 2026 is a meaningful editorial positive worth highlighting — buyers can compare $175 standard and $155 microdose against competitor headlines in seconds rather than completing a qualification quiz first. The LegitScript-display gap is real, but it doesn't invalidate the pricing transparency win.— Bartley Editorial Analysis

Ivy RX vs alternatives

If you want a microdose tier at a published price, Ivy RX's $155 is competitive with SkinnyRx's $149.25 — but SkinnyRx prominently displays its LegitScript probationary status while Ivy RX displays no LegitScript status at all. If absolute lowest published price is your priority, Oak ($133) wins clearly. If LegitScript visibility matters most, Medvi or Fella are stronger trust-stack choices at slightly higher prices.

Ivy RX GLP-1 pros and cons

Ivy RX sign-up & ongoing-care checklists

If you decide Ivy RX is the right fit, the three checklists below cover the practical details most buyers wish they'd known before signing up.

Ivy RX frequently asked questions

Honest verdict — should you choose Ivy RX?

Ivy RX earns its 4.1/5 editor's rating on one structural pricing positive that genuinely matters in the 2026 U.S. telehealth GLP-1 market: published pricing. Where FuturHealth, Elevate Health, and Fella Health (for GLP-1 specifically) gate their pricing behind qualification quizzes, Ivy RX publishes $175 standard GLP-1, $155 microdose, and $199 NAD+ directly on the landing page. The $155 microdose tier is competitive with SkinnyRx ($149.25) and FeelGood ($149) at the entry level, and the platform's same-day physician review plus 2-day medication delivery is fast by category standards. The longevity-positioned care with NAD+ as a primary product (not just a wellness add-on) is structurally distinctive — and the honest direct compounded-vs-FDA disclosure ("The FDA does not review compounded medications for safety or effectiveness") is unusually transparent. 200,000+ patient claim provides meaningful scale evidence.

What pulls the rating down from a higher mark is a specific verification gap worth taking seriously: Ivy RX does not display LegitScript certification status on its landing page. Most competitors we've reviewed in 2026 — including Medvi (full), Fella Health (full), FuturHealth (full), and even SkinnyRx (probationary, but openly disclosed) — prominently display LegitScript certification status. The absence on Ivy RX's landing page isn't necessarily a red flag (the platform may hold LegitScript certification and simply not display the seal, or it may not), but it does mean buyers should verify status directly on LegitScript's public merchant lookup database before assuming certification. A secondary smaller issue: the review-count discrepancy (5,000+ cited in some places, 4,000+ in the footer with a 4.5 rating) is a minor copy hygiene issue worth flagging for editorial scrutiny.

Expert advice: who should sign up for Ivy RX today

Sign up for Ivy RX if any of the following apply to you:

• You value published pricing transparency. $175 GLP-1, $155 microdose, $199 NAD+ — visible without applying first. In a category where many platforms gate pricing, this is a real editorial positive.
• You'd benefit from the microdose tier at $155/month. Useful for patients prone to early GI side effects, slow titration preferences, or low-dose maintenance protocols.
• You want NAD+ as a primary product, not just a wellness add-on. Ivy RX's longevity-positioning treats NAD+ as substantive offering.
• You value speed. 5-minute assessment + same-day physician review + 2-day medication delivery is faster than most competitors.
• You appreciate honest disclosure. Ivy RX's direct "the FDA does not review compounded medications" framing is admirably transparent.
• You can pay with FSA or HSA funds. Both accepted at checkout.
• You're willing to verify LegitScript status directly on LegitScript's merchant database rather than relying on landing-page seals — and you're comfortable with that extra verification step.

The bottom line

If you value published pricing, want a microdose tier at $155/month with NAD+ as a primary product alongside GLP-1, and are willing to verify LegitScript certification status directly on LegitScript's public merchant database — Ivy RX is a structurally interesting choice in the 2026 U.S. telehealth GLP-1 market. If LegitScript visibility on the merchant's own site is a non-negotiable trust signal for you, Medvi, Fella, FuturHealth, or even SkinnyRx (probationary but openly disclosed) are stronger third-party-certification choices.

Published: June 3, 2026 · Last updated: June 3, 2026 · Pricing & certifications verified: June 2026 · Spot a factual issue? Tell our editors.